Symptoms of Pancreatic Atrophy
Pancreatic atrophy primarily manifests through symptoms of exocrine pancreatic insufficiency (EPI), including steatorrhea, weight loss, bloating, excessive flatulence, fat-soluble vitamin deficiencies, and protein-calorie malnutrition. 1
Core Clinical Features
The symptom profile of pancreatic atrophy directly reflects the loss of functional pancreatic tissue and resulting enzyme deficiency:
Gastrointestinal Symptoms
- Steatorrhea (fatty stools) with or without diarrhea—the hallmark manifestation of inadequate lipase secretion 1
- Bloating and excessive flatulence from maldigestion of nutrients 1
- Diarrhea may be present but is not universal 1
Nutritional Consequences
- Progressive weight loss despite adequate caloric intake, due to malabsorption 1
- Protein-calorie malnutrition from impaired digestion of macronutrients 1
- Fat-soluble vitamin deficiencies (vitamins A, D, E, K) leading to:
Body Composition Changes
- Loss of muscle mass and muscle function, measurable through handgrip strength and body mass index decline 1
- Failure to recover body weight even with adequate caloric intake 2
Important Clinical Context
Relationship Between Atrophy and Symptoms
Pancreatic atrophy is independently associated with exocrine pancreatic dysfunction (EPD), even when corrected for other factors reducing exocrine capacity. 3 However, a critical nuance exists:
- Pain and other symptoms have a complex pathogenesis independent of the degree of atrophy or fibrosis visible on imaging 4
- Fibrosis, atrophy, and ductal pathology correlate with pancreatic function (exocrine and endocrine insufficiency) but not with pain severity 4
- This means patients may have severe atrophy with minimal pain, or significant pain with minimal atrophy 4
Endocrine Manifestations
While less common than exocrine symptoms, pancreatic atrophy can lead to:
- Diabetes mellitus from loss of islet cells, particularly in long-standing disease 5, 4
- Elevated glycated hemoglobin levels correlating with degree of atrophy 4
High-Risk Conditions Associated with Atrophy
Suspect pancreatic atrophy and its associated symptoms in patients with: 1
- Chronic pancreatitis (most common cause)
- Pancreatic ductal adenocarcinoma
- Previous pancreatic surgery
- Cystic fibrosis
- Relapsing acute pancreatitis
- Drug-induced pancreatic injury (e.g., immune checkpoint inhibitors) 6
- Post-hematopoietic cell transplantation with chronic graft-versus-host disease 2
Diagnostic Considerations
Key Imaging Findings
- Pancreatic atrophy appears as reduced pancreatic size on cross-sectional imaging (CT or MRI) 3
- Specific cutoffs for clinically relevant atrophy: sum of maximal axial dimension of pancreatic head and body <31 mm for females and <37.5 mm for males 3
- Imaging cannot directly identify EPI but plays an important role in diagnosing underlying pancreatic disease 1
Functional Testing
- Fecal elastase <100 µg/g provides good evidence of EPI when measured on semi-solid or solid stool 1
- Levels 100-200 µg/g are indeterminate 1
- Watery stools cause false-low results; testing should only be performed on formed stool 7
Clinical Pitfalls
- Therapeutic trials of pancreatic enzymes are unreliable for diagnosis and should not be used to confirm EPI 1, 7
- Duodenal diseases (celiac disease, Crohn's disease) can lower fecal elastase values without true pancreatic insufficiency 7
- Untreated EPI from pancreatic atrophy results in complications related to fat malabsorption and malnutrition, negatively impacting quality of life 1
Management Implications
Once symptoms of pancreatic atrophy (manifesting as EPI) are identified:
- Pancreatic enzyme replacement therapy (PERT) is required, starting with at least 40,000 USP units of lipase with each meal 1
- Routine supplementation and monitoring of fat-soluble vitamin levels are appropriate 1
- Successful treatment measures include reduction in steatorrhea, weight gain, improved muscle mass and function, and normalization of vitamin levels 1